drugset / Trial / NCT04878770
NMF-CsA-Dupi Trial
Unknown
318 enrolled
Erasmus Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The goal of this study is to investigate whether stratification of children with atopic dermatitis on the NMF biomarkers results in an improvement of effectiveness and efficiency in the use of systemic treatment (ciclosporin and dupilumab) in moderate-to-severe atopic dermatitis.
Timeline
- Start
- 2021-08-16
- Primary completion
- 2024-01-01
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 2 mg/kg | Oral |
| Comparator | Cyclosporine | Peptide | 3 mg/kg | Oral |
| Comparator | Cyclosporine | Peptide | 4 mg/kg | Oral |
| Comparator | Cyclosporine | Peptide | 5 mg/kg | Oral |
| Comparator | Dupilumab | Monoclonal antibody | — | Other |